NASDAQ:SABS SAB Biotherapeutics Q3 2025 Earnings Report $2.29 -0.21 (-8.40%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$2.35 +0.06 (+2.40%) As of 10/10/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast SAB Biotherapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.59Beat/MissN/AOne Year Ago EPSN/ASAB Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASAB Biotherapeutics Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time7:00AM ETConference Call ResourcesEarnings HistoryCompany Profile SAB Biotherapeutics Earnings HeadlinesSAB Biotherapeutics highlights data in multiple presentations at EASDSeptember 19, 2025 | msn.comSAB BIO Highlights Data in Multiple Presentations at EASDSeptember 19, 2025 | globenewswire.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.October 11 at 2:00 AM | Brownstone Research (Ad)Leerink Partners Initiates Coverage of SAB Biotherapeutics (SABS) with Outperform RecommendationSeptember 18, 2025 | msn.comSAB Biotherapeutics initiated with an Outperform at LeerinkSeptember 17, 2025 | msn.comSAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of DiabetesSeptember 3, 2025 | markets.businessinsider.comSee More SAB Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SAB Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your email. Email Address About SAB BiotherapeuticsSAB Biotherapeutics (NASDAQ:SABS) is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use. The company’s lead programs are directed primarily at infectious diseases. SAB-185, its anti-SARS-CoV-2 polyclonal antibody candidate, advanced through clinical trials for the treatment and prevention of COVID-19. In addition to its coronavirus program, SAB Biotherapeutics is exploring pipeline candidates against other emerging pathogens, including Zika virus, MERS, and chikungunya virus. Beyond infectious disease, the Tc Bovine® platform has potential applications in oncology and chronic inflammatory conditions, where diverse antibody repertoires may address antigenic variation and tumor heterogeneity. Since its founding in 2008, SAB Biotherapeutics has pursued strategic collaborations with government agencies, academic institutions, and industry partners to accelerate development of its antibody therapeutics. The company operates its biomanufacturing and research facilities in Sioux Falls and maintains collaborations across the United States for preclinical and clinical studies. By leveraging its transchromosomic cattle system, SAB Biotherapeutics aims to provide a rapid response capability for emerging public-health threats, while building a diversified pipeline of immune-based therapies for multiple indications.View SAB Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)America Movil (10/14/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
